Clinical Trials Logo

Hypothalamic Obesity clinical trials

View clinical trials related to Hypothalamic Obesity.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT05774756 Enrolling by invitation - Clinical trials for Hypothalamic Obesity

A Trial of Setmelanotide in Acquired Hypothalamic Obesity

Start date: April 26, 2023
Phase: Phase 3
Study type: Interventional

The goal of this trial is to learn how well Setmelanotide works to improve weight reduction, hunger, and quality of life in patients 4 years of age and older with acquired Hypothalamic Obesity (HO). To determine how well setmelanotide works and how safe it is, patients with HO will take a daily injection of either setmelanotide or placebo and complete trial assessments for up to 60 weeks.